Association Between Clinical Backgrounds and Malignant Progression of Suspected Intraductal Papillary Mucinous Neoplasm.
Journal
Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
pubmed:
14
9
2022
medline:
12
10
2022
entrez:
13
9
2022
Statut:
ppublish
Résumé
Some intraductal papillary mucinous neoplasms (IPMNs) have malignant potential and can become pancreatic cancer. The mechanism behind the malignant progression of IPMN remains unknown. We aimed to identify the risk factors and interactions between backgrounds for IPMN. We retrospectively enrolled 980 patients of pancreatic cancer or suspected IPMN (sIPMN) who underwent endoscopic ultrasound or retrograde cholangiopancreatography. We classified them into pancreatic cancer, high-risk sIPMN, and low-risk sIPMN, and investigated the risk factors for high-risk sIPMN. Smoking habits (odds ratio [OR], 3.74; 95% confidence interval [CI], 2.04-6.85; P < 0.001), serum carbohydrate antigen 19-9 ≥37 U/mL (OR, 6.30; 95% CI, 2.88-13.80; P < 0.001), and family history of cancers (OR, 2.38; 95% CI, 1.30-4.37; P = 0.005) were independent risk factors for high-risk suspected IPMN. Odds ratios of diabetes and neutrophil-to-lymphocyte ratio of 2.45 or greater were significantly higher in patients with a family history of cancer than those without a family history of cancer (OR, 3.28; 95% CI, 0.52-20.80 vs 1.85; 95% CI, 0.78-4.41; OR, 2.44; 95% CI, 0.81-7.34 vs 1.24; 95% CI, 0.67-2.30, respectively). Understanding the interactions between background factors can effectively prevent IPMNs' malignant transformation.
Identifiants
pubmed: 36099509
doi: 10.1097/MPA.0000000000002064
pii: 00006676-202207000-00010
doi:
Substances chimiques
Carbohydrates
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
617-623Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol . 2019;10:10–27.
Egawa S, Toma H, Ohigashi H, et al. Japan Pancreatic Cancer Registry; 30th year anniversary. Japan Pancreas Society. Pancreas . 2012;41:985–992.
Ansari D, Bauden M, Bergström S, et al. Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma. Br J Surg . 2017;104:600–607.
Capasso M, Franceschi M, Rodriguez-Castro KI, et al. Epidemiology and risk factors of pancreatic cancer. Acta Biomed . 2018;89:141–146.
Nakano Y, Kitago M, Shinoda M, et al. Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study. Cancer Med . 2017;6:2278–2286.
Yokose T, Kitago M, Matsuda S, et al. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer. Cancer Sci . 2020;111:2174–2182.
Yamaguchi K, Okusaka T, Shimizu K, et al. Clinical practice guidelines for pancreatic cancer 2016 from the Japan Pancreas Society. Pancreas . 2017;46:595–604.
McGuigan A, Kelly P, Turkington RC, et al. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol . 2018;24:4846–4861.
Midha S, Chawla S, Garg PK. Modifiable and non-modifiable risk factors for pancreatic cancer: a review. Cancer Lett . 2016;381:269–277.
Jiao L, Mitrou PN, Reedy J, et al. A combined healthy lifestyle score and risk of pancreatic cancer in a large cohort study. Arch Intern Med . 2009;169:764–770.
Khannoussi W, Vullierme MP, Rebours V, et al. The long term risk of malignancy in patients with branch duct intraductal papillary mucinous neoplasms of the pancreas. Pancreatology . 2012;12:198–202.
Abe K, Kitago M, Masugi Y, et al. Indication for resection and possibility of observation for intraductal papillary mucinous neoplasm with high-risk stigmata. Pancreatology . 2021;21:755–762.
Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology . 2012;12:183–197.
Tanaka M, Fernández-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology . 2017;17:738–753.
Gemenetzis G, Bagante F, Griffin J, et al. Neutrophil-to-lymphocyte ratio is a predictive marker for invasive malignancy in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg . 2017;266:339–345.
Iwai N, Okuda T, Sakagami J, et al. Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer. Sci Rep . 2020;10:18758.
Mowbray N, Griffith D, Hammoda M, et al. A meta-analysis of the utility of the neutrophil-to-lymphocyte ratio in predicting survival after pancreatic cancer resection. HPB (Oxford) . 2018;20:379–384.
Brentnall TA, Bronner MP, Byrd DR, et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann lntern Med . 1999;131:247–255.
Kitago M, Ueda M, Aiura K, et al. Comparison of K-ras point mutation distributions in intraductal papillary-mucinous tumors and ductal adenocarcinoma of the pancreas. Int J Cancer . 2004;110:177–182.
Fujita Y, Matsuda S, Sasaki Y, et al. Pathogenesis of multiple pancreatic cancers involves multicentric carcinogenesis and intrapancreatic metastasis. Cancer Sci . 2020;111:739–748.
Fujita Y, Kitago M, Masugi Y, et al. Two cases of pancreatic ductal adenocarcinoma with intrapancreatic metastasis. World J Gastroenterol . 2016;22:9222–9228.
Matsubayashi H, Maeda A, Kanemoto H, et al. Risk factors of familial pancreatic cancer in Japan: current smoking and recent onset of diabetes. Pancreas . 2011;40:974–978.
Bo X, Shi J, Liu R, et al. Using the risk factors of pancreatic cancer and their interactions in cancer screening: a case-control study in Shanghai, China. Ann Glob Health . 2019;85:103.
Abe K, Ueki A, Urakawa Y, et al. Familial pancreatic cancer with PALB2 and NBN pathogenic variants: a case report. Hereditary Cancer Clin Pract . 2021;19:5.
Young EL, Thompson BA, Neklason DW, et al. Pancreatic cancer as a sentinel for hereditary cancer predisposition. BMC Cancer . 2018;18:697.
Pittman ME, Brosens LA, Wood LD. Genetic syndromes with pancreatic manifestations. Surg Pathol . 2016;9:705–715.
Rustgi AK. Familial pancreatic cancer: genetic advances. Genes Dev . 2014;28:1–7.
Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut . 2013;62:339–347.
Canto MI, Almario JA, Schulick RD, et al. Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance. Gastroenterology . 2018;155:740–751.e2.
Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut . 2020;69:7–17.
Daly M, Pal T, Buys S, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw . 2021;19:77–102. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1503 . Accessed March 2, 2022.
Singhi AD, Koay EJ, Chari ST, et al. Early detection of pancreatic cancer: opportunities and challenges. Gastroenterology . 2019;156:2024–2040.